Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Dizal Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:688192'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.38 Med: -0.27 Max: -0.05
Current: -2.38
During the past 8 years, the highest Debt-to-EBITDA Ratio of Dizal Pharmaceutical Co was -0.05. The lowest was -2.38. And the median was -0.27.
SHSE:688192's Debt-to-EBITDA is ranked worse than 100% of 675
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SHSE:688192: -2.38
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Dizal Pharmaceutical Co Debt-to-EBITDA Related Terms
Dizal Pharmaceutical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dizal Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dizal Pharmaceutical Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dizal Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dizal Pharmaceutical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Dizal Pharmaceutical Co (SHSE:688192) has a Debt-to-EBITDA of -3.16 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dizal Pharmaceutical Co. According to the industry distribution chart, Dizal Pharmaceutical Co ranks #999999 out of 675 companies in the Drug Manufacturers industry.
Is Dizal Pharmaceutical Co's Debt-to-EBITDA too high?
Dizal Pharmaceutical Co's current Debt-to-EBITDA is -3.16. Based on the distribution chart, Dizal Pharmaceutical Co ranks #999999 out of 675 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dizal Pharmaceutical Co has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dizal Pharmaceutical Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dizal Pharmaceutical Co ranks #999999 out of 675 companies for Debt-to-EBITDA. This places Dizal Pharmaceutical Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 675 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dizal Pharmaceutical Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dizal Pharmaceutical Co's current Debt-to-EBITDA is -3.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dizal Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co (SHSE:688192) is currently considered Possible Value Trap. The stock's GF Value™ is ¥116.88, compared to a current price of ¥57.07 — trading 51.2% below its estimated fair value. The current Debt-to-EBITDA is -3.16. Dizal Pharmaceutical Co's overall GF Score™ is 32/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Dizal Pharmaceutical Co (SHSE:688192), the current Debt-to-EBITDA is -3.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dizal Pharmaceutical Co (SHSE:688192) Overvalued in 2026?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥57.07 is trading 51.2% below its estimated GF Value™ of ¥116.88.
GuruFocus considers Dizal Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for SHSE:688192:
Debt-to-EBITDA: -3.16
GF Value™: ¥116.88 vs. price of ¥57.07 (51.2% below fair value)
No single metric tells the full story. See the SHSE:688192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
32GF Score
Get the complete analysis for SHSE:688192
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688192 has been successfully added to your 
